——————————————————————————– ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Contracts/LifeWatch AG 31.01.2012 Neuhausen am Rheinfall / Switzerland – LifeWatch AG (SIX Swiss Exchange: LIFE), the leading wireless remote cardiac and medical patient monitoring service provider in the U.S., [...]
Tag Archive > Clinical Outcomes
CAPRELSA? (vandetanib) Receives Positive CHMP Opinion in the European Union for Treating Advanced Medullary Thyroid Cancer
London, November 18 (ots/PRNewswire) – AstraZeneca today announced that the Marketing Authorisation Application for CAPRELSA (vandetanib) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. The proposed indication also states [...]
EANS-Adhoc: LifeWatch announces total 2011 contracts year to date for ACT and Home Sleep testing services (with document)
——————————————————————————– ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Company Information/Lifewatch AG 25.10.2011 Neuhausen am Rheinfall/Switzerland – LifeWatch AG (SIX Swiss Exchange: LIFE), the leading wireless remote cardiac and medical patient monitoring service provider in the U.S., announced [...]
Breast Cancer Research and Treatment Highlights Development and Validation of BluePrint®
Irvine, California and Amsterdam (ots/PRNewswire) – – Peer-Reviewed Article Notes That Multi-Gene Subtyping Profile Provides Deeper Insight Into Breast Cancer Agendia, an innovative molecular cancer diagnostics company, today announced that a published report highlighting the development and validation of its 80-gene BluePrint breast cancer profile was published online in Breast Cancer Research and Treatment, a [...]
Astellas Receives Positive Opinion From CHMP for European Approval of VIBATIV(TM) for Nosocomial Pneumonia Caused by MRSA
Staines, England (ots/PRNewswire) – Astellas Pharma Europe Ltd., announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of marketing authorisation for VIBATIV (telavancin hydrochloride) for the treatment for adults with nosocomial (hospital-acquired) pneumonia, including ventilator associated pneumonia known or [...]
Biovista Inc. erhält renommierte EU-Subvention zwecks Einsatz von Technologie zur Arzneimittel-Umpositionierung für personalisierte Medizin
CHARLOTTESVILLE, Virginia, USA und ATHEN, Griechenland, May 5, 2011 (ots/PRNewswire) — Biovista Inc. gab heute eine prestigeträchtige Subvention in Höhe von 0,5 Millionen US-Dollar bekannt, die der europäischen Schwestergesellschaft des Unternehmens eingeräumt wurde. Der Betrag soll für Forschung und Entwicklung im Bereich personalisierter Medizin angewandt werden. Das Projekt “p-medicine” ist ein über vier Jahre laufendes [...]
International Society for Cellular Therapy (ISCT) Launches Inaugural Cell Therapy Commercial Development Focus Group on Peripheral Vascular Disease
Vancouver (ots/PRNewswire) – In keeping with its commitment to connect industry, regulatory experts, therapeutic societies and translational centers to advance emerging cellular therapies, ISCT announces its first commercial development focus group addressing Cell Therapies for Peripheral Vascular Disease (PVD). PVD is a condition in which the arteries that carry blood to the arms or legs [...]
EANS-Adhoc: LifeWatch Announces New "AF TeleClinic"
——————————————————————————– ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– New Products/LifeWatch AG 11.05.2010 First in Series of Treatment-Specific Remote Patient Monitoring Services Chicago, IL / USA May 11 2010 – LifeWatch Services, Inc., a subsidiary of LifeWatch AG [...]
Daten-Präsentation aus dem Multiple-Sklerose-Portfolio von Merck Serono auf der Tagung der Amerikanischen Akademie für Neurologie
Genf, Schweiz (ots) – Präsentation neuer Daten auf der AAN-Jahrestagung zur Therapie mit Rebif® sowie der in der Prüfung befindlichen Therapie mit Cladribin Tabletten unterstreicht das Engagement von Merck Serono an der Multiplen Sklerose-Forschung und Behandlung. Merck Serono, eine Sparte der Merck KGaA, Darmstadt, Deutschland, gab heute bekannt, dass das Unternehmen anlässlich der vom 10. [...]
First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes
Orlando, Florida, November 15 (ots/PRNewswire) – Results from the RecordAF registry (REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation), presented today at the Scientific Sessions of the American Heart Association, show that in recently diagnosed and actively treated patients with atrial fibrillation (AF), a rhythm-control strategy provides better short term control of [...]
Abbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International Markets
Barcelona, Spain (ots/PRNewswire) – – New Cobalt Chromium Stent Offers Enhanced Deliverability with a Broad Matrix of Sizes – Built Upon the Proven Track Record of Superior Clinical Outcomes of Abbott’s Market-Leading XIENCE V(R) Drug Eluting Stent Abbott (NYSE: ABT) today announced at the European Society of Cardiology Congress the widespread availability of its next-generation [...]
